Humedics, G2Bio, and Hanguk Pharma Sign Joint Development Agreement for Long-Lasting Dementia Treatment
1-Month Long-Acting Donepezil Injection
From the left, Jinwhan Kim, CEO of Humedics; Heeyong Lee, CEO of G2G Bio; Eunhee Park, CEO of Korea Pharma.
View original image[Asia Economy Reporter Lee Gwan-joo] Humedix announced on the 5th that it has signed a contract with G2G Bio and Korea Pharma for the joint development and licensing of a donepezil injection for the treatment of Alzheimer's dementia.
Through this contract, Humedix plans to develop the existing donepezil oral drug into an improved injectable new drug to create a new market. G2G Bio will be responsible for the formulation development and production of the donepezil injection, which maintains efficacy in the body for one month by applying the InnoLAMP platform technology, while Humedix and Korea Pharma will handle clinical trials, product approval, and sales. Humedix and Korea Pharma will pay G2G Bio technology fees and a certain percentage of royalties upon future product commercialization, and hold domestic distribution rights.
G2G Bio's InnoLAMP technology is a proprietary sustained-release platform that uses biodegradable polymers to manufacture uniform microparticles, ensuring stable and prolonged efficacy when administered in the body.
Donepezil is the most prescribed ingredient among Alzheimer's dementia treatments. While the existing daily oral medication is difficult for dementia patients to swallow or take on time due to memory decline, the collaborative product maintains consistent efficacy for one month with a single administration, improving medication adherence. It also significantly reduces the burden on caregivers who need to manage the patient's medication.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Woman Experiences Eye Protrusion After 20 Years of Contraceptive Injections, Plans Lawsuit Against Major Pharmaceutical Company
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Jin-hwan Kim, CEO of Humedix, said, “Through close cooperation with the promising bio-technology company G2G Bio and the highly capable Korea Pharma, we will pioneer the future competitive field of sustained-release injectable drugs and build a stronger partnership.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
